Oruka Therapeutics Inc (ORKA)
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapies for psoriasis and other inflammatory and immunology-related conditions. The company’s pipeline includes ORKA-001, a Phase 2a candidate designed to target the p19 subunit of interleukin-23 for psoriasis, and ORKA-002, a Phase 2 candidate aimed at interleukin-17A and interleukin-17F for psoriasis, psoriatic arthritis, and additional indications. Oruka is also advancing ORKA-003, which is being developed against an undisclosed pathway, along with ORKA-021, a sequential combination regimen involving ORKA-002 and ORKA-001. The company is headquartered in Menlo Park, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ORKA
|
$55.19
|
-41.9% Downside
|
Overvalued
|
$155
|
63.2% Upside
|
Bargain
|
Good
|
0.0%
|
November 18, 2026
|
5.8x
|
6.276 B
|
5.362 B
|
0.0%
|
85.9%
|
152.0
|
92.2%
|
